

Subject: Reminder: DATA-Waiver Program

[DEA Announces Important Change to Registration Requirement](#)

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.”

This message is to remind DEA registrants of the following:

- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
- In Pennsylvania, no current state laws or regulations prohibit practitioners from adopting this change.

Separately, the Act also introduced new training requirements for all prescribers. **These requirements will go into effect on June 21, 2023.** The DEA and SAMHSA are actively working to provide further guidance and DEA will follow up with additional information on these requirements.

Please contact the Diversion Control Division Policy Section at ODLP@dea.gov for additional guidance.